Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiGlobeNewsWire • 01/25/23
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage DiseasesGlobeNewsWire • 01/09/23
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialGlobeNewsWire • 12/05/22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRNGlobeNewsWire • 11/01/22
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/24/22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common StockGlobeNewsWire • 10/20/22
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's Disease Associated with LRRK2 Pathogenic MutationsGlobeNewsWire • 10/03/22
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?Zacks Investment Research • 09/29/22
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?Zacks Investment Research • 09/07/22
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022GlobeNewsWire • 08/31/22
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 08/08/22
Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/27/22
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's DiseaseGlobeNewsWire • 05/31/22
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 05/05/22
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by SanofiGlobeNewsWire • 05/02/22
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/25/22